RxDoctor Payments Data

Sheena Ausirus, APRN

Psychiatric/Mental Health · Hollywood, FLNPI 1346739356

Payments from drug & device makers

$4,184in general payments, 2019–2025

Across 138 payments — averaging $30.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Vanda Pharmaceuticals Inc.$715
  • Johnson & Johnson$601
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$488
  • Otsuka America Pharmaceutical, Inc.$455
  • E.r. Squibb & Sons, L.L.C.$359
  • plus $317 from 3 others

What the payments were for

  • Food & beverage$4,15699%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,184 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$10,160
Medicare patients
72
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate68$214,808
IngrezzaValbenazine Tosylate15$118,333
Abilify MaintenaAripiprazole37$107,068
AristadaAripiprazole Lauroxil33$98,106
VraylarCariprazine Hcl13$21,731
Aripiprazole90$15,490
Ziprasidone Hcl47$5,420
Haloperidol Decanoate75$3,553
Haloperidol62$2,150
Benztropine Mesylate164$1,704
Mirtazapine114$1,627
Lurasidone Hcl39$1,516
Buspirone Hcl159$1,440
Divalproex Sodium ErDivalproex Sodium24$1,324
Bupropion Hcl SrBupropion Hcl61$1,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$601$214,80868 claims
Neurocrine Biosciences, Inc.Ingrezza$55$118,33315 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$455$107,06837 claims
Alkermes, Inc.Aristada$220$98,10633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →